airways compared to the blood, and the frequency of Mtb-specific CD153-expressing CD4 T cells inversely correlates with bacterial loads in granulomas. Further, in Mtb infected humans, CD153 defines a subset of highly polyfunctional Mtb-specific CD4 T cells that are much more abundant in individuals with controlled latent Mtb infection compared to those with active TB. Since the expression of CD153 by CD4 T cells is a major immune mechanism of host protection against Mtb infection, the discovery can be used to effectively diagnose and treat Mtb infections in the future.

This technology is available for licensing for commercial development in accordance with 35 U.S.C. 209 and 37 CFR part 404, as well as for further development and evaluation under a research collaboration.

Potential Commercial Applications:

- **Mycobacterium tuberculosis** diagnostic that measures the production of CD153 as an indicator of the disease and its severity
- A companion diagnostic can be used to determine the effectiveness of a vaccine against a **Mycobacterium tuberculosis** infection in a subject
- Therapeutic use to treat **Mycobacterium tuberculosis** in a subject

**Competitive Advantages:**

- Ability to be used as a target for Mtb diagnostics and therapeutics
- Development Stage:
  - Proof of concept in animal models and human subject.

**Inventors:** Daniel L. Barber (NIAID), Michelle A. Sallin (NIAID), Keith D. Kaufman (NIAID)


**Licensing Contact:** James M. Robinson, 301–761–7542; James.Robinson4@nih.gov.

**Collaborative Research Opportunity:** The National Institute of Allergy and Infectious Diseases is seeking statements of capability or interest from parties interested in collaborative research to further develop, evaluate or commercialize the methods of treating human tuberculosis. For collaboration opportunities, please contact James M. Robinson at 301–761–7542 or James.Robinson4@nih.gov.


**Suzanne M. Frishie,**
Deputy Director, Technology Transfer and Intellectual Property Office, National Institute of Allergy and Infectious Diseases.

[FR Doc. 2018–24469 Filed 11–7–18; 8:45 am]

BILLING CODE 4140–01–P

DEPARTMENT OF HEALTH AND HUMAN SERVICES

National Institutes of Health

Center for Scientific Review; Notice of Closed Meetings

Pursuant to section 10(d) of the Federal Advisory Committee Act, as amended, notice is hereby given of the following meetings.

The meetings will be closed to the public in accordance with the provisions set forth in sections 552b(c)(4) and 552b(c)(6), Title 5 U.S.C., as amended. The grant applications and the discussions could disclose confidential trade secrets or commercial property such as patentable material, and personal information concerning individuals associated with the grant applications, the disclosure of which would constitute a clearly unwarranted invasion of personal privacy.

**Name of Committee:** Center for Scientific Review Special Emphasis Panel; Neurodevelopmental Disorders.

**Date:** November 20, 2018.
**Time:** 12:00 p.m. to 5:00 p.m.
**Agenda:** To review and evaluate grant applications.
**Place:** National Institutes of Health, 6701 Rockledge Drive, Bethesda, MD 20892.

**Contact Person:** Pat Manos, Ph.D., Scientific Review Officer, Center for Scientific Research, National Institutes of Health, 6701 Rockledge Drive, Room 5200, MSC 7846, Bethesda, MD 20892, 301–408–9866, manospa@csr.nih.gov.

**Name of Committee:** Center for Scientific Review Special Emphasis Panel; PAR Review: Cancer Behavioral Research Communication in the New Media Environment.

**Date:** November 30, 2018.
**Time:** 10:30 a.m. to 5:00 p.m.
**Agenda:** To review and evaluate grant applications.
**Place:** National Institutes of Health, 6701 Rockledge Drive, Bethesda, MD 20892.

**Contact Person:** Terez Shea-Donohue, Ph.D., Scientific Review Officer, Center for Scientific Review, National Institutes of Health, 6701 Rockledge Drive, Room 2180, MSC 7818, Bethesda, MD 20892, sheandonohue@nih.gov.


Dated: November 2, 2018.

**Sylvia L. Neal,**
Program Analyst, Office of Federal Advisory Committee Policy.

[FR Doc. 2018–24466 Filed 11–7–18; 8:45 am]

BILLING CODE 4140–01–P